PRNewsWire
01 Jan 2026, 14:00 UTC · 38w ago
Verdict
Headline leans bearish. We score INV −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Telix's BLA due to manufacturing (CMC) and Form 483 deficiencies at third-party partners.
More negative than 99% of claims this week
The SEC has issued a subpoena to Telix Pharmaceuticals regarding its development disclosures.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 98% of claims this week
Telix is facing a securities class action lawsuit alleging it misrepresented the progress of its prostate cancer drug TLX591 and its manufacturing capabilities.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company faces a securities class action lawsuit after its stock price dropped 55%.
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following an SEC subpoena, FDA manufacturing failures, and a 21% stock plunge.
More negative than 86% of ticker scores this week
The company and its executives are facing a securities class action lawsuit stemming from FTC actions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
−80.0%
Price agrees with the score
$0.8377 vs $4.18 close before publication (Dec 31) · not market-adjusted
INV chart →
